Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr

Kiniksa Pharmaceuticals International, plc

Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.
Decision not due to any disagreement with the company on operations, policies, or practices.
Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.
Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.
Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eben Tessari

special advisor to the Company's Science and Research Committee

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").

Departed

Eben Tessari

Chief Strategy Officer

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Eben Tessari was appointed as special advisor to the Company's Science and Research Committee at Kiniksa Pharmaceuticals International, plc.

Action: appointed
Role: special advisor to the Company's Science and Research Committee

Exact text from the filing

Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eben Tessari resigned as Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc.

Action: resigned
Role: Chief Strategy Officer

Exact text from the filing

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

View on SEC.gov

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001730430-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.